期刊
NEUROLOGY
卷 76, 期 23, 页码 1989-1995出版社
LIPPINCOTT WILLIAMS & WILKINS
DOI: 10.1212/WNL.0b013e31821e552a
关键词
-
资金
- National Multiple Sclerosis Society
- University of California
- San Francisco
- Stony Brook
- Buffalo
- University of Alabama Birmingham
- Harvard University
- Mayo Clinic
- NIH [K23NS067055, RR015577, AI082714, U19AI082714, AR053483]
- Nancy Davis Foundation
- NMSS [RG2901D9/1]
- National MS Society
- National NS Society
- Partners MS Center
- Acorda Therapeutics Inc.
- Bayer Schering Pharma
- Biogen Idec
- EMD Serono, Inc.
- Genentech, Inc.
- Teva Pharmaceutical Industries Ltd.
- Novartis
- sanofi-aventis
- GlaxoSmithKline
- MS Association of America
- France Foundation
- Eli Lilly and Company
- MedImmune
- Vertex Pharmaceuticals
- Wyeth
- ZymoGenetics
- EPI-Q
- Genzyme Corporation
- Tibotec Therapeutics
- Roche
- Johnson Johnson
- Janssen
- ER Squibb Sons
- NIH/NINDS
- NIH
- Jake Foundation
- Children's Guild Foundation
- Spinal Muscular Atrophy Foundation
- Cooperative International Neuromuscular Research Group/U. S. Department of Education
- Pfizer Inc
- Mayo Rehabilitation Research Training Center
- Conrad Hilton Foundation
- Donald and Frances Herdrich Foundation
- Canadian MS Society
- Morphotek
Background: Because common viruses are encountered during childhood, pediatric multiple sclerosis (MS) offers a unique opportunity to investigate the influence of these viruses on disease susceptibility and the interactions between seroprevalence and select HLA genotypes. We studied seroprevalence for Epstein-Barr virus (EBV), cytomegalovirus (CMV), and herpes simplex virus (HSV) type 1 and HLA-DRB1*1501/1503 status as predictors of pediatric MS. Methods: This was a retrospective analysis of prospectively collected demographic, clinical, and biologic data in subjects up to 18 years of age with early MS, control subjects seen at the same regional referral pediatric MS clinics, and additional healthy pediatric control subjects. Results: Patients with early pediatric MS (n = 189) and pediatric control subjects (n = 66) were tested. Epstein-Barr nuclear antigen-1 seropositivity was associated with an increased odds of MS (odds ratio [OR] 3.78, 95% confidence interval [CI] 1.52-9.38, p = 0.004) in analyses adjusted for age, sex, race, ethnicity, and HLA-DRB1*1501/1503 status. In multivariate analyses including EBV status, a remote infection with CMV (OR 0.27,95% CI 0.11-0.67, p = 0.004) was associated with a lower risk of developing MS. Although a remote infection with HSV-1 was not associated with an increased odds of MS, a strong interaction was found between HSV-1 status and HLA-DRB1 in predicting MS (p < 0.001). HSV-1 was associated with an increased risk of MS in those without a DRB1*15 allele (OR 4.11, 95% CI 1.17-14.37, p = 0.03), whereas the effect was reversed in those who were DRB1*15-positive (OR 0.07, 95% CI 0.02-0.32, p = 0.001). Conclusions: These findings suggest that some infections with common viruses may in fact lower MS susceptibility. If this is confirmed, the pathways for risk modification remain to be elucidated. Neurology (R) 2011;76:1989-1995
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据